Nektar Therapeutics Reports Q3 2026 Revenue of $9.4 Million and Net Loss of $55.7 Million

Nektar Therapeutics reported third-quarter 2026 revenue of $9.4 million, down from $11.8 million a year earlier, and a net loss of $55.7 million. The company ended September with $952.9 million in cash and marketable securities. Its Phase 3 program for rezpegaldesleukin advanced in atopic dermatiti…